PATENT CLAIM ANALYSIS

Application Number: 16193407
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "009600"]

Abstract:
The teachings provide active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Methods of making and using the systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Claim (Index 7):
The enhanced active agent of  claim 2 , the drug having an increased half-life in blood serum when conjugated to the delivery system.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 98.0
- Lexical Diversity: 1.82
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15446212', '14000594', '14166719', '13415790', '11178736']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6872556468289199
- 35 USC 102 Novelty (BERT): 0.6250928190959723
- Combined Prediction Score: 0.6810393640556253
- Mean Citation Score: 331.6680760000001
- Max Citation Score: 680.1484
- Similarity Product: 477.331463746357

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test